Episode Details
Back to Episodes
MapLight CFO Sells Shares, Biotech's Summer Tests Loom
Description
MapLight Therapeutics CFO, Setia Vishwas, sold over 36,000 shares, netting $1.2 million, in a pre-arranged plan from December 2025. Despite the sale, Vishwas still holds over 356,000 shares worth $10.35 million. The company, focused on brain disorders, has seen a 70% stock jump but is still in the red due to clinical trial costs. The summers data readouts will determine their success, making it a high-risk, high-reward situation for investors.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/3bad85c77f2d221c